Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMMX Immix Biopharma, Inc.

Pre-Mkt 04-08 08:02:34 EDT

9.09

+0.50

+5.82%

盘前9.36

+0.27+2.97%

07:19 EDT

High9.18	Low8.26	Vol856.32K
Open8.52	D1 Closing8.59	Amplitude10.71%
Mkt Cap481.36M	Tradable Cap376.68M	Total Shares52.96M
T/O7.52M	T/O Rate2.07%	Tradable Shares41.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":9.09,"timestamp":1775592000000,"preClose":8.59,"halted":0,"volume":856315,"hourTrading":{"tag":"盘前","latestPrice":9.36,"preClose":9.09,"latestTime":"07:19 EDT","volume":242,"amount":2265.12,"timestamp":1775647159462,"change":0.27,"changeRate":0.029703,"amplitude":0},"delay":0,"changeRate":0.05820721769499418,"floatShares":41439399,"shares":52955100,"eps":-0.893007,"marketStatus":"Pre-Mkt","change":0.5,"latestTime":"04-08 08:02:34 EDT","open":8.52,"high":9.18,"low":8.26,"amount":7517120.980695001,"amplitude":0.107101,"askPrice":9.6,"askSize":600,"bidPrice":8.65,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-0.893007,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775655000000},"marketStatusCode":1,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":9.09,"preHourTrading":{"tag":"盘前","latestPrice":9.36,"preClose":9.09,"latestTime":"07:19 EDT","volume":242,"amount":2265.12,"timestamp":1775647159462,"change":0.27,"changeRate":0.029703,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":9.23,"preClose":9.09,"latestTime":"18:45 EDT","volume":5789,"amount":52610.92,"timestamp":1775601946977,"change":0.14,"changeRate":0.015402,"amplitude":0.070407},"volumeRatio":1.1337769853949804,"impliedVol":0.9161,"impliedVolPercentile":0.241},"requestUrl":"/m/hq/s/IMMX/wiki","defaultTab":"wiki","newsList":[{"id":"2625860127","title":"Immix Biopharma announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2625860127","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625860127?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:38","pubTimestamp":1775507928,"startTime":"0","endTime":"0","summary":"Immix Biopharma scheduled annual shareholder meeting in Los Angeles on May 22, 2026.Shareholders will vote to elect nine directors to serve until next annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL846Dx5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623898765","title":"Infinimmune: Under Agreement, Merck Will Have Exclusive Right to Develop and Commercialize Antibody Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2623898765","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623898765?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:05","pubTimestamp":1774958720,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J1EC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJJMRZ35.SGD","LU1934455863.HKD","SG9999001440.SGD","SG9999002232.USD","LU0203345920.USD","IE00BBT3K403.USD","LU1989772840.SGD","IE00B4R5TH58.HKD","LU0211331839.USD","LU1023059063.AUD","LU0006306889.USD","LU0070302665.USD","LU1037948541.HKD","LU1929549753.HKD","LU1093756325.SGD","LU0965509101.SGD","LU1974910355.USD","LU1066051498.USD","LU1291159041.SGD","SG9999014559.SGD","LU1989772923.USD","LU0861579265.USD","LU0985320562.USD","IE00BLSP4239.USD","LU2361044865.SGD","LU0106261372.USD","LU1983299246.USD","LU1585245621.USD","IE000M9KFDE8.USD","IE00BN8TJ469.HKD","LU1116320737.USD","LU1057294990.SGD","BK4550","LU1066051225.USD","LU0238689110.USD","IE00BJT1NW94.SGD","LU1934455194.USD","LU1934455277.USD","SG9999015341.SGD","BK4559","SG9999014542.SGD","LU0130102774.USD","LU1201861249.SGD","LU0477156953.USD","LU2461242641.AUD","BK4585","LU1941712264.USD","LU0130517989.USD","SG9999013999.USD","IE00BFTCPJ56.SGD","LU0868494708.USD","LU0980610538.SGD","LU1066051811.HKD","LU1066053197.SGD","LU1989771016.USD","SG9999014575.USD","LU1035773651.USD","LU0320765646.SGD","BK4516","SG9999001176.SGD","LU1917777945.USD","LU0098860793.USD","LU0965509010.AUD","IE0009355771.USD","LU2468319806.SGD","LU2360032135.SGD","LU0942090050.USD","LU2023250504.SGD","LU1941712348.USD","LU1061106388.HKD","LU2106854487.HKD","LU0289739699.SGD","LU0432979614.USD","IE00B2B36J28.USD","SG9999014567.USD","LU1699723380.USD","LU0203347892.USD","LU0868494617.USD","LU2125154935.USD","LU0965509283.SGD","LU2361045086.USD","BK4533","LU0058720904.USD","LU2089984988.USD","IE00B1BXHZ80.USD","SG9999001176.USD","BK4588","LU1037948897.HKD","SGXZ57979304.SGD","BK4007","LU0234572021.USD","LU1093756168.USD","LU0648001328.SGD","LU2023250843.SGD","SG9999002224.SGD","LU1116320901.HKD","MRK","LU0208291251.USD","LU0265550359.USD","LU0320765489.SGD","IE0002141913.USD","LU2125154778.USD","BK4534","LU0122379950.USD","LU0965508806.USD","LU1430594728.SGD","LU0265550946.USD","LU1162221912.USD","LU1571399168.USD","IMMX","IE00BSNM7G36.USD","SG9999015358.SGD","IE00BLSP4452.SGD","LU0266013472.USD","LU1069347547.HKD","LU2361044949.HKD","LU2324357040.USD","LU2112291526.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623328908","title":"Immix Biopharma Price Target Maintained With a $15.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2623328908","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623328908?lang=en_us&edition=fundamental","pubTime":"2026-03-31 01:43","pubTimestamp":1774892580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 13:43 ET (17:43 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623459893","title":"Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon","url":"https://stock-news.laohu8.com/highlight/detail?id=2623459893","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623459893?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:38","pubTimestamp":1774877922,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced that NEXICART-2 enrollment is complete, meeting company guidance, with topline results expected in Q3, followed by...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-completes-nexicart-2-enrollment-onboards-cmo-richard-graydon-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-completes-nexicart-2-enrollment-onboards-cmo-richard-graydon-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623310705","title":"Immix Biopharma completes enrollment in NEXICART-2 AL amyloidosis BLA-enabling trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623310705","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623310705?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:45","pubTimestamp":1774874730,"startTime":"0","endTime":"0","summary":"Immix Biopharma completed enrollment in NEXICART-2, its BLA-enabling trial in relapsed or refractory AL amyloidosis.Positive interim data were previously presented at ASH 2025.Topline NEXICART-2 results are expected in Q3 2026.BLA submission is planned following topline results, with commercial launch planned thereafter.Richard Graydon joined as chief medical officer to support BLA submission.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL8f0s4m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4585","BK4139","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","NDAQ","IE00B64PRP62.GBP","IMMX","BK4588","BK4112","SG9999014039.USD","LU2095319765.USD","LU2210150020.SGD","SG9999014013.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014021.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623310711","title":"Immix Biopharma Announces Enrollment Completion of Bla-Enabling Relapsed/Refractory Al Amyloidosis Trial Nexicart-2, and Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2623310711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623310711?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:45","pubTimestamp":1774874700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA7FGJWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622823988","title":"Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2622823988","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622823988?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:08","pubTimestamp":1774609680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 07:08 ET (11:08 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847028","title":"Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $15 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847028?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:11","pubTimestamp":1774606293,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nAZN4SNMI4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622845792","title":"U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845792","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622845792?lang=en_us&edition=fundamental","pubTime":"2026-03-27 15:54","pubTimestamp":1774598066,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex HoldingsMarch 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL4N40F0FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTGO","ATAI","DIS","GOOGL","LU1815333072.USD","PHAT","DISO","IE00BMPRXQ63.HKD","GOOX","CHRD","GGLL","CMC","OLPX","COP","GOOP","GGLS","BK4551","SPXC","IT","BALY","MGTX","PL","CCL","ADP","BK4561","KOD","EOG","GOU","PLU","IMMX","OXY","HAL","LU0345769128.USD","GOOW","AGX","FISV","KYIV","GNRC","OXM","NHI","GOOY","UNX","BK4134","CTAS","FOXA","LBRX","MASI","U","PRMB","BIOA"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622860508","title":"Immix Biopharma, Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622860508","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622860508?lang=en_us&edition=fundamental","pubTime":"2026-03-26 08:57","pubTimestamp":1774486675,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc reports results for the quarter ended December 31 - Earnings SummaryImmix Biopharma, Inc IMMX.OQ reported a quarterly adjusted loss of 28 cents per share for the quarter ended Dec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E00Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000248","title":"Immix Biopharma Q4 EPS $(0.28) Misses $(0.16) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000248","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000248?lang=en_us&edition=fundamental","pubTime":"2026-03-26 06:13","pubTimestamp":1774476811,"startTime":"0","endTime":"0","summary":"Immix Biopharma (NASDAQ:IMMX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.16) by 75 percent. This is a 75 percent decrease over losses of $(0.16) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51472287/immix-biopharma-q4-eps-0-28-misses-0-16-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Immix Biopharma Q4 EPS $(0.28) Misses $(0.16) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622007039","title":"Immix Biopharma Inc - Enters Amendment No. 1 to Atm Offering Agreement on March 25, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622007039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622007039?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:25","pubTimestamp":1774473912,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D11X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622007741","title":"Immix Biopharma amends at-the-market equity distribution agreement; offering size holds at $100 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622007741","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622007741?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:24","pubTimestamp":1774473865,"startTime":"0","endTime":"0","summary":"Immix Biopharma entered Amendment No. 1 to its at-the-market equity distribution agreement with Citizens JMP Securities, allowing sales of common stock with aggregate offering proceeds of up to USD 100.0 million.Citizens JMP Securities will act as sales agent and receive a 3% commission on gross sales proceeds.Share sales may be executed in at-the-market transactions, including privately negotiated and block transactions.The company agreed to reimburse specified agent expenses related to entering the sales agreement up to USD 50,000.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL6Wdb0F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622007200","title":"Immix Biopharma FY2025 operating loss widens 43.73% to $29.4 million; revenue is not available","url":"https://stock-news.laohu8.com/highlight/detail?id=2622007200","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622007200?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:20","pubTimestamp":1774473604,"startTime":"0","endTime":"0","summary":"Immix Biopharma published its annual report  for the fiscal year ended Dec. 31, 2025, reporting a net loss of USD 29.4 million.General and administrative expenses rose 20.35% to USD 13.7 million, driven by higher compensation from additional hires as well as increased investor relations and professional services costs.Research and development expenses increased 43.98% to USD 16.3 million, reflecting higher clinical trial and related costs, and were offset by USD 2.7 million of CIRM grant reimbursements recorded as a reduction of R&D expense.Interest income fell 45.39% to USD 555,526 as the company maintained lower balances in money market funds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL69V33T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622072826","title":"Immix Biopharma Initiated at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072826","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072826?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:23","pubTimestamp":1774448580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2026 10:23 ET (14:23 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622102647","title":"Immix Biopharma initiated with an Overweight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2622102647","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622102647?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:55","pubTimestamp":1774428910,"startTime":"0","endTime":"0","summary":"Morgan Stanley initiated coverage of Immix Biopharma (IMMX) with an Overweight rating and $20 price target The company is developing NXC-201, a BCM...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-initiated-with-an-overweight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-initiated-with-an-overweight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1244550494.USD","LU0234570918.USD","LU2028103732.USD","LU0528227936.USD","LU1668664300.SGD","LU0006306889.USD","LU0795875169.SGD","LU2089283258.USD","LU2089284900.SGD","LU2347655156.SGD","LU0882574139.USD","LU1363072403.SGD","IMMX","LU1791710582.SGD","LU1732799900.SGD","BK4127","BK4588","LU0267386448.USD","LU1720051108.HKD","BK4139","LU1989772923.USD","LU2271345857.HKD","BK4516","LU0912757837.SGD","LU0314104364.USD","BK4534","LU1244550577.SGD","LU0795875086.SGD","LU0158827948.USD","LU0557290698.USD","LU0971096721.USD","LU2023251221.USD","LU2111349929.HKD","LU2357305700.SGD","LU1548497426.USD","BK4581","LU1791710400.SGD","LU0098860793.USD","IE00BZ1G4Q59.USD","LU1162221912.USD","LU1720051017.SGD","LU0106261372.USD","LU0320765646.SGD","LU1732800096.USD","LU0158827781.USD","LU1074936037.SGD","IE00BKVL7J92.USD","LU0106831901.USD","LU2133065610.SGD","LU1989772840.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621751216","title":"Immix Biopharma, Inc  expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621751216","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621751216?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:32","pubTimestamp":1774038740,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc  expected to post a loss of16cents a share - Earnings Preview Immix Biopharma, Inc IMMX.OQ IMMX.O is expected to  show no change in quarterly revenue when it reports  results on M","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N4082AP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618640333","title":"Immix Biopharma Initiated at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640333","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640333?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:53","pubTimestamp":1773053580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 06:53 ET (10:53 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618649223","title":"Immix Biopharma initiated with an Outperform at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2618649223","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618649223?lang=en_us&edition=fundamental","pubTime":"2026-03-09 16:50","pubTimestamp":1773046220,"startTime":"0","endTime":"0","summary":"Citizens initiated coverage of Immix Biopharma (IMMX) with an Outperform rating and $23 price target The firm says the company’s NXC-201 has demons...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-initiated-with-an-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-initiated-with-an-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617598947","title":"Immix Biopharma Publishes Corporate Presentation on NXC-201 BCMA CAR-T for Relapsed/Refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2617598947","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617598947?lang=en_us&edition=fundamental","pubTime":"2026-03-05 08:18","pubTimestamp":1772669934,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. released a corporate presentation outlining its focus on NXC-201, a BCMA-targeted CAR-T therapy being studied for relapsed or refractory AL amyloidosis. The presentation states that relapsed or refractory AL amyloidosis has no FDA-approved therapies and cites an estimated 38,500 relapsed or refractory patients in the U.S. It also summarizes clinical data presented at ASH in December 2025, including a reported 75 percent complete response rate for NXC-201 in this setting, and describes planned clinical and commercial milestones, including a registrationally designed NEXICART-2 trial and a commercial launch plan in the first half of 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL9k8Tsz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immixbio.com","stockEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":-0.0215},{"period":"3month","weight":0.8},{"period":"6month","weight":2.5233},{"period":"1year","weight":5.0199},{"period":"ytd","weight":0.738}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":-0.0196},{"period":"3month","weight":-0.044},{"period":"6month","weight":-0.0178},{"period":"1year","weight":0.307},{"period":"ytd","weight":-0.0333}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.035123},{"month":2,"riseRate":0.2,"avgChangeRate":-0.05746},{"month":3,"riseRate":0.2,"avgChangeRate":-0.065433},{"month":4,"riseRate":0.4,"avgChangeRate":-0.021929},{"month":5,"riseRate":0.5,"avgChangeRate":0.112474},{"month":6,"riseRate":0.5,"avgChangeRate":0.09241},{"month":7,"riseRate":0.5,"avgChangeRate":0.015932},{"month":8,"riseRate":0.25,"avgChangeRate":-0.104667},{"month":9,"riseRate":0.25,"avgChangeRate":0.017421},{"month":10,"riseRate":0.75,"avgChangeRate":0.171445},{"month":11,"riseRate":1,"avgChangeRate":0.264693},{"month":12,"riseRate":1,"avgChangeRate":0.380003}],"exchange":"NASDAQ","name":"Immix Biopharma, Inc.","nameEN":"Immix Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immix Biopharma, Inc.,IMMX,Immix Biopharma, Inc.股票,Immix Biopharma, Inc.股票老虎,Immix Biopharma, Inc.股票老虎国际,Immix Biopharma, Inc.行情,Immix Biopharma, Inc.股票行情,Immix Biopharma, Inc.股价,Immix Biopharma, Inc.股市,Immix Biopharma, Inc.股票价格,Immix Biopharma, Inc.股票交易,Immix Biopharma, Inc.股票购买,Immix Biopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}